BioSpace News Archive

Vera Therapeutics, Inc. announced that on June 4, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units for 14,500 shares of Class A common stock to five new employees under Vera’s 2024 Inducement Plan.

Structure Therapeutics Inc. announced the closing of its previously announced upsized underwritten public offering of 10,427,017 American depositary shares, each representing three ordinary shares, including the full exercise of the underwriters’ option to purchase up to 1,360,045 additional ADSs, at a public offering price of $52.50 per ADS.

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced the results of its Annual Meeting of shareholders.

ORIC Pharmaceuticals, Inc. announced that on June 3, 2024, ORIC granted a total of 30,000 non-qualified stock options and 4,800 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2024.

Gossamer Bio, Inc. announced that the Compensation Committee of Gossamer’s Board of Directors approved the grant, effective June 5, 2024, to one new non-executive employee of non-qualified stock option awards to purchase up to an aggregate of 170,000 shares of the Company’s common stock under the Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan.

Incyte announced that it granted restricted stock unit awards representing an aggregate of 14,090 shares of the Company’s common stock and stock option awards to purchase an aggregate of 9,238 shares of the Company’s common stock to 17 new employees.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:.

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia” or the “Company”), today announced that it is undertaking a private placement of unsecured debenture units.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee.